

Durvalumab with paclitaxel/carboplatin and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer without a tumor *BRCA1/BRCA2* mutation: results from the randomized, placebo-controlled Phase III DUO-O/ENGOT-ov46/AGO-OVAR 23/GOG-3025 trial

Philipp Harter,¹ Fabian Trillsch,² Aikou Okamoto,³ Alexander Reuss,⁴ Jae-Weon Kim,⁵ Maria Jesús Rubio-Pérez,⁶ Mehmet Ali Vardar,⁷ Giovanni Scambia,⁸ Olivier Trédan,⁹ Gitte-Bettina Nyvang,¹⁰ Nicoletta Colombo,¹¹ Anita Chudecka-Głaz,¹² Christoph Grimm,¹³ Stephanie Lheureux,¹⁴ Els Van Nieuwenhuysen,¹⁵ Florian Heitz,¹⁶ Robert M. Wenham,¹⁷ Kimio Ushijima,¹⁸ Emily Day,¹⁹ Carol Aghajanian²⁰

¹Kliniken Essen-Mitte, Essen, and AGO, Germany; ²University Hospital, LMU Munich, Munich, and AGO, Germany; ³The Jikei University School of Medicine, Tokyo, and JGOG, Japan; ⁴Coordinating Center for Clinical Trials of the Philipps-University of Marburg, Marburg, and ENGOT, Germany; ⁵ Seoul National University Hospital, Seoul, and KGOG, South Korea; ⁶Reina Sofia University Hospital, Cordoba, and GEICO, Spain; ⁷Medical Faculty, University of Cukurova, and Balcali Hospital, Adana, and TRSGO, Turkey; ⁸Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, and MITO, Italy; ⁹Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, and GINECO, France; ¹⁰ Odense Universitetshospital, Odense, and NSGO, Denmark; ¹¹University of Milan-Bicocca and Istituto Europeo di Oncologia IRCCS, Milan, and MANGO, Italy; ¹²SPSK Nr 2, Pomeranian Medical University, Szczecin, and PGOG, Poland; ¹³Gynecologic Cancer Unit, Medical University Vienna, and AGO-Au, Austria; ¹⁴Princess Margaret Hospital, Toronto, ON, and PMHC, Canada; ¹⁵UZ Leuven, Leuven, and BGOG, Belgium, ¹⁶Ev. Kliniken Essen-Mitte, Essen, and Charité Campus Virchow-Klinikum, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, and AGO, Germany; ¹⁷Moffitt Cancer Center, Tampa, FL, and GOG-F, USA; ¹⁸Kurume University School of Medicine, Kurume, and JGOG, Japan; ¹⁹Oncology Biometrics, AstraZeneca, Cambridge, UK; ²⁰Memorial Sloan Kettering Cancer Center, New York, NY, and GOG-F, USA

ClinicalTrials.gov identifier: NCT03737643 This study was sponsored by AstraZeneca

#ASCO23





ASCO^{*} AMERICAN SOCIETY OF CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER

Background

#ASCO23


- Maintenance therapy with olaparib ± bevacizumab has improved outcomes in first-line advanced OC.^{1,2} However, unmet need remains, especially in some non-BRCAm patient subgroups
- To date, Phase III trials investigating the addition of immuno-oncology agents to standard of care in the newly diagnosed advanced OC setting have yet to demonstrate clinical benefit^{3,4}
- However, in the Phase II MEDIOLA study, the combination of durvalumab + bevacizumab + olaparib has shown promising clinical activity in patients with non-gBRCAm PSR OC⁵
- The Phase III DUO-O study evaluates paclitaxel/carboplatin + bevacizumab + durvalumab followed by maintenance therapy with bevacizumab + durvalumab + olaparib in patients with newly diagnosed non-tBRCAm advanced OC
- We report results of the preplanned interim PFS analysis from the DUO-O study

1. DiSilvestro P *et al. J Clin Oncol* 2023;41:609–17; 2. Ray-Coquard IL *et al. Ann Oncol* 2022;33(Suppl. 7):abstr LBA29; 3. Moore KN *et al. J Clin Oncol* 2021;39:1842–55; 4. Monk BJ *et al. Lancet Oncol* 2021;22:1275–89; 5. Banerjee S *et al. Ann Oncol* 2022;33(Suppl. 7):abstr 529MO. BRCAm, *BRCA1* and/or *BRCA2* mutation; gBRCAm, germline BRCAm; OC, ovarian cancer; PFS, progression-free survival; PSR, platinum-sensitive relapsed; tBRCAm, tumor BRCAm.





DUO-O study design



Treatment continued until disease progression, study treatment was complete or other discontinuation criteria were met

Dosing and schedule: bevacizumab (15 mg/kg IV g3w); durvalumab (1120 mg IV g3w); olaparib (300 mg po bid); chemotherapy; paclitaxel 175 mg/m² IV g3w and carboplatin at AUC5 or AUC6 IV g3w. PFS interim analysis DCO: December 5, 2022. *With or without bevacizumab according to local practice; [†]Cycles 2–6; [‡]Genomic instability score ≥42 assessed prospectively by Myriad MyChoice CDx assay.

AUC, area under the curve; bev, bevacizumab; bid, twice daily; CTx, chemotherapy; DCO, data cutoff; durva, durvalumab; FIGO, International Federation of Gynecology and Obstetrics; HRD, homologous recombination deficiency; ITT, intent-to-treat; IV, intravenous; ola, olaparib; OS, overall survival; PC, paclitaxel/carboplatin; po, by mouth; g3w, every 3 weeks; R, randomization; RECIST, Response Evaluation Criteria for Solid Tumors.




PRESENTED BY: Dr Philipp Harter #ASCO23

2023 **ASCO**

ANNUAL MEETING

DUO-O study design



Treatment continued until disease progression, study treatment was complete or other discontinuation criteria were met

Dosing and schedule: bevacizumab (15 mg/kg IV q3w); durvalumab (1120 mg IV q3w); olaparib (300 mg po bid); chemotherapy: paclitaxel 175 mg/m² IV q3w and carboplatin at AUC5 or AUC6 IV q3w. PFS interim analysis DCO: December 5, 2022. *With or without bevacizumab according to local practice; [†]Cycles 2–6; [‡]Genomic instability score ≥42 assessed prospectively by Myriad MyChoice CDx assay.

AUC, area under the curve; bev, bevacizumab; bid, twice daily; CTx, chemotherapy; DCO, data cutoff; durva, durvalumab; FIGO, International Federation of Gynecology and Obstetrics; HRD, homologous recombination deficiency; ITT, intent-to-treat; IV, intravenous; ola, olaparib; OS, overall survival; PC, paclitaxel/carboplatin; po, by mouth; q3w, every 3 weeks; R, randomization; RECIST, Response Evaluation Criteria for Solid Tumors.




PRESENTED BY: Dr Philipp Harter #ASCO23

2023 **ASCO**

ANNUAL MEETING

Multiple testing procedure and PFS interim analysis



CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER

PRESENTED BY: Dr Philipp Harter #ASCO23

ANNUAL MEETING

Patient characteristics

Characteristics		Arm 1 PC + bev N=378	Arm 2 PC + bev + durva N=374	Arm 3 PC + bev + durva + ola N=378	Characteristics		Arm 1 PC + bev N=378	Arm 2 PC + bev + durva N=374	Arm 3 PC + bev + durva + ola N=378
Age, years	Median age (range)	59.0 (32–83)	58.0 (29–85)	61.0 (21–84)	Surgery status at	Upfront primary surgery	58	59	63
Geographical	Europe	66	66	66	study entry, %	Planned IDS	42	41	37
region,* %	North America	12	12	12	Timing and outcome of	No macroscopic residual disease after	38	38	38
	Rest of world	22	22	22	cytoreductive	upfront surgery			
FIGO stage, [†] %	III	63	69	67	surgery (as per stratification),* %	Macroscopic residual	62	62	62
	IV	37	31	33	Stratification), 70	disease after upfront			
ECOG status, %	0	64	69	69		surgery OR			
	1	36	31	31		Planned interval			
Histology, %	High-grade serous	88	87	90		debulking surgery			
	Clear cell	5	6	3	HRD status,§ %	HRD-positive	38	40	37
	High-grade endometrioid	3	2	2		HRD-negative	57	53	56
	Other [‡]	4	5	5		Unknown	5	7	7

Percentages may not total 100 because of rounding.

*Per IRT; †One patient in Arm 2 had unknown FIGO stage; ‡Includes mixed epithelial, carcinosarcoma and other

histology types; §Genomic instability assessed using the Myriad MyChoice CDx assay and a cutoff of 42.

ECOG, Eastern Cooperative Oncology Group; IDS, interval debulking surgery; IRT, interactive response technology.





2023 **ASCO**

ANNUAL MEETING

Patient disposition

		Arm 1 PC + bev N=378	Arm 2 PC + bev + durva N=374	Arm 3 PC + bev + durva + ola N=378
Randomized, n (%)		378 (100)	374 (100)	378 (100)
Received any treatment/started maintenance phase, n (%)		378 (100)/331 (88)	374 (100)/323 (86)	378 (100)/336 (89)
	Durvalumab/placebo	376 (99)	373 (100)	378 (100)
	Olaparib/placebo	331 (88)	323 (86)	336 (89)
	PC + bevacizumab	378 (100)	374 (100)	378 (100)
Still receiving treatment at DCO, n (%)	Durvalumab/placebo	39 (10)	34 (9)	58 (15)
	Olaparib/placebo	53 (16)	63 (20)	65 (19)
	Bevacizumab	7 (2)	8 (2)	15 (4)
	Carboplatin	0 (0)	0 (0)	0 (0)
	Paclitaxel	0 (0)	0 (0)	0 (0)
Median (range) duration of treatment, months	Durvalumab/placebo*	16.4 (0.0–46.0)	13.8 (0.5–35.9)	17.3 (0.7–40.5)
	Olaparib/placebo [†]	14.3 (0.7–42.5)	14.2 (0.2–34.3)	14.8 (0.2–36.8)
	Bevacizumab*	14.7 (0.0–26.7)	14.4 (0.7–22.3)	15.2 (0.7–26.0)
Median no. of cycles (range)	Carboplatin [‡]	6 (2–6)	6 (2–6)	6 (2–6)
	Paclitaxel§	6 (1–6)	6 (1–8)	6 (1–7)
Median (range) duration of follow up, ^{II} months		25.5 (0.0-44.8)	23.1 (0.0-42.6)	23.3 (0.0-41.7)

Patients who discontinued one or more study treatment could continue to receive the remaining study treatments.

Percentages may not total 100 because of rounding.

*Total period from first dose to earliest date of last non-zero dose +20 days, death or DCO; †Total period from first dose of olaparib/placebo to earliest date of last non-zero dose, death or DCO; ‡Carboplatin or cisplatin substitute; \$Paclitaxel or nab-paclitaxel, docetaxel or pegylated liposomal doxorubicin substitute; In patients censored for PFS.



#ASCO23 PRESENTED BY: Dr Philipp Harter


Across all arms, ~90% of patients completed

all planned cycles of chemotherapy

2023 **ASCO**

ANNUAL MEETING

PFS: Non-tBRCAm HRD-positive population Arm 3 vs Arm 1



*In censored patients; †Medians and rates were estimated by KM method; ‡Median PFS in Arm 3 unstable; §HR and CI were estimated from a stratified Cox proportional hazards model. *P* value from a stratified log rank text. Model stratified by timing and outcome of cytoreductive surgery; ^I24-month PFS rates unstable. CI, confidence interval; HR, hazard ratio; KM, Kaplan–Meier.



Arm 1

PC + bev

Arm 3

PC + bev +

#ASCO23 PRESENTED BY: Dr Philipp Harter

2023 **ASCO**


ANNUAL MEETING

PFS: ITT population Arm 3 vs Arm 1

2023 **ASCO**

ANNUAL MEETING

#ASCO23



*In censored patients; [†]Medians and rates were estimated by KM method; [‡]HR and CI were estimated from a stratified Cox proportional hazards model. Model stratified by timing and outcome of cytoreductive surgery and geographical region. *P* value from a stratified log rank text; [§]24-month PFS rates unstable.



Arm 1


PC + bev

Arm 3

PC + bev +

PRESENTED BY: Dr Philipp Harter

PFS: ITT population



*In censored patients; [†]Medians and rates were estimated by KM method; [‡]HR and CI were estimated from a stratified Cox proportional hazards model. Model stratified by timing and outcome of cytoreductive surgery and geographical region. *P* value from a stratified log rank text; [§]24-month PFS rates unstable.

Arm 1

Arm 2

Arm 3




#ASCO23 PRESENTED BY: Dr Philipp Harter

2023 **ASCO**

ANNUAL MEETING

Subgroup analysis of PFS by HRD status



	Arm 1 PC + bev N=143	Arm 3 PC + bev + durva + ola N=140
Events, n (%)	86 (60)	49 (35)
Median PFS, months [†]	23.0	37.3 [‡]
HR (95% CI) vs Arm 1		0.51 (0.36–0.72)§

#ASCO23

2023 **ASCO**

ANNUAL MEETING


	Arm 1 PC + bev N=216	Arm 3 PC + bev + durva + ola N=211
Events, n (%)	157 (73)	127 (60)
Median PFS, months [†]	17.4	20.9
HR (95% CI) vs Arm 1		0.68 (0.54–0.86)§

*24-month PFS rates unstable; [†]Medians and rates were estimated by KM method; [‡]Median PFS in HRD-positive subgroup Arm 3 and Arm 2 unstable; [§]HR and CI were estimated from an unstratified Cox proportional hazards model.



PRESENTED BY: Dr Philipp Harter

Subgroup analysis of PFS by HRD status



	Arm 1 PC + bev N=143	Arm 2 PC + bev + durva N=148	Arm 3 PC + bev + durva + ola N=140
Events, n (%)	86 (60)	69 (47)	49 (35)
Median PFS, months [†]	23.0	24.4 [‡]	37.3 [‡]
HR (95% CI) vs Arm 1		0.82 (0.60–1.12)§	0.51 (0.36–0.72)§

ASCO

ANNUAL MEETING

#ASCO23

HRD-negative Patients free from disease progression or death (%) 76% 64% 67% 40% 63% 42% 31% 24% Time from randomization (months) Patients at risk Arm 1 Arm 2 Arm 3

	Arm 1 PC + bev N=216	Arm 2 PC + bev + durva N=199	Arm 3 PC + bev + durva + ola N=211
Events, n (%)	157 (73)	142 (71)	127 (60)
Median PFS, months [†]	17.4	15.4	20.9
HR (95% CI) vs Arm 1		0.94 (0.75–1.18)§	0.68 (0.54–0.86)§

*24-month PFS rates unstable; †Medians and rates were estimated by KM method; ‡Median PFS in HRD-positive subgroup Arm 3 and Arm 2 unstable; §HR and CI were estimated from an unstratified Cox proportional hazards model.



PRESENTED BY: Dr Philipp Harter

Subgroup analyses of PFS Arm 3 vs Arm 1 (ITT population)

	Arm 3 PC + bev + durva + ola N=378	Arm 1 PC + bev N=378					
	Events, n/N (%)	Events, n/N (%)	HR (95% CI)				
All patients	193/378 (51)	259/378 (69)	0.64 (0.53-0.77)	⊢ ●−−1			
Time and outcome of cytoreductive surgery			· · · · · ·				
No macroscopic residual disease after upfront primary surgery	58/144 (40)	82/144 (57)	0.64 (0.46-0.90)	⊢ – – – – – – – – – –			
All others*	135/234 (58)	177/234 (76)	0.62 (0.49-0.77)	⊢ – – – – – – – – – – – – – – – – – – –			
Geographic region		()					
North America	22/45 (49)	36/45 (80)	0.62 (0.36-1.04)	⊢			
Europe	132/250 (53)	169/250 (68)	0.64 (0.51–0.80)	⊢ ● <u></u> −1			
Rest of world	39/83 (47)	54/83 (65)	0.65 (0.43-0.98)	⊢			
Age at screening			(/				
<65 years	123/243 (51)	181/268 (68)	0.65 (0.51-0.81)	⊢_ ●1			
≥65 years	70/135 (52)	78/110 (71)	0.63 (0.45–0.87)	• • • • • • • • • • • • • • • • • • •			
ECOG performance status							
0 (normal activity)	118/259 (46)	154/242 (64)	0.61 (0.48-0.78)	⊢_ ●I			
1 (restricted activity)	75/119 (63)	105/136 (77)	0.72 (0.53-0.97)	· · · · · · · · · · · · · · · · · · ·			
Stage of disease at diagnosis		,					
	121/254 (48)	147/238 (62)	0.70 (0.55–0.89)	⊢ ● − 1			
IV	72/124 (58)	112/140 (80)	0.55 (0.41–0.74)	⊢ − ● −−−1			
Surgery status at study entry							
Upfront primary surgery	110/237 (46)	141/221 (64)	0.64 (0.50-0.82)	⊢			
Planned IDS	83/141 (59)	118/157 (75)	0.66 (0.50-0.87)	⊢ ●			
Myriad HRD status							
HRD-positive	49/140 (35)	86/143 (60)	0.51 (0.36–0.72)	⊢ 1			
HRD-negative	127/211 (60)	157/216 (73)	0.68 (0.54–0.86)	⊢			
HRD unknown	17/27 (63)	16/19 (84)	0.50 (0.25–1.01)	• • · · · · · · · · · · · · · · · · · ·			
PD-L1 (TAP5) expression [†]	- ()						
TAP5 high	61/142 (43)	85/141 (60)	0.67 (0.48–0.93)	⊢ − ● −−−1			
TAP5 low	118/215 (55)	156/201 (78)	0.58 (0.46–0.74)	⊢ −−−1			
TAP5 unknown	14/21 (67)	18/36 (50)	1.11 (0.54–2.24)		•		
				0.25 0.5 1.0	1.5	2.0	2.5
				 Favors Arm 3 	Favors Arm 1		

Consistency of treatment effect between subgroups estimated from an unstratified Cox proportional hazards model.

*Macroscopic residual disease after upfront surgery OR planned interval debulking surgery; [†]PD-L1 expression was centrally assessed by Ventana SP263 immunohistochemistry assay. Tumor area positivity PD-L1 expression (TAP5): high defined as ≥5%; low defined as <5%; unknown defined as samples where PD-L1 expression was not available. PD-L1, programmed death-ligand 1.



PRESENTED BY: Dr Philipp Harter

2023 **ASCO**

ANNUAL MEETING

#ASCO23

Safety summary

	(chemothera	Overall py phase + mair	all Maintenance pha maintenance phase)			ase	
AEs, n (%)	Arm 1 PC + bev N=376	Arm 2 PC + bev + durva N=373	Arm 3 PC + bev + durva + ola N=378	Arm 1 PC + bev N=331	Arm 2 PC + bev + durva N=323	Arm 3 PC + bev + durva + ola N=336	
Any-grade AE	373 (99)	371 (99)	375 (99)	308 (93)	303 (94)	328 (98)	
Grade ≥3 AE	231 (61)	245 (66)	269 (71)	88 (27)	113 (35)	164 (49)	
AE with outcome of death	4 (1)	9 (2)	6 (2)	2 (1)	3 (1)	4 (1)	
Serious AE (including outcome of death)	128 (34)	161 (43)	148 (39)	50 (15)	91 (28)	83 (25)	
AE of special interest to olaparib							
MDS/AML*	1 (<1)	0	2 (1)	1 (<1)	0	1 (<1)	
New primary malignancies*	1 (<1)	1 (<1)	4 (1)	1 (<1)	1 (<1)	3 (1)	
Pneumonitis	3 (1)	5 (1)	7 (2)	1 (<1)	3 (1)	6 (2)	
Any immune-mediated AEs [†]	132 (35)	209 (56)	200 (53)	94 (28)	139 (43)	141 (42)	
AEs leading to dose modification ^{‡,§}	272 (72)	299 (80)	323 (85)	163 (49)	182 (56)	254 (76)	
AEs leading to discontinuation [‡]	77 (20)	98 (26)	131 (35)	44 (13)	54 (17)	88 (26)	
AEs leading to discontinuation of PC/bevacizumab	57 (15)	59 (16)	70 (19)	27 (8)	24 (7)	35 (10)	
AEs leading to discontinuation of durvalumab/placebo	24 (6)	62 (17)	65 (17)	14 (4)	39 (12)	40 (12)	
AEs leading to discontinuation of olaparib/placebo	15 (4)	19 (5)	62 (16)	14 (4)	19 (6)	61 (18)	

Includes AEs with onset or worsening on or after the date of first dose of durvalumab/placebo or olaparib/placebo (overall) or first dose of olaparib/placebo (maintenance phase)

until initiation of the first subsequent anticancer therapy following last dose of study treatment or until the end of the safety follow-up period.

*Includes events from first dose of durvalumab/olaparib/placebo until end of study; †Investigator-assessed; ‡Based on action taken on AE CRF for at least one treatment. For durvalumab/placebo, dose modification includes skipped or delayed doses, or interruption of the infusion; [§]Either dose reduction or dose interruption. AE, adverse event; AML, acute myeloid leukemia; CRF, case report form; MDS, myelodysplastic syndrome.





2023 **ASCO**

ANNUAL MEETING

Any AE with frequency of ≥20%*

	Overall (chemotherapy phase + maintenance phase)				Maintenance phase			
AEs	Arm 1 PC + bev	Arm 2 PC + bev + durva	Arm 3 PC + bev + durva + ola	Arm 1 PC + bev	Arm 2 PC + bev + durva	Arm 3 PC + bev + durva + ola		
	N=376	N=373	N=378	N=331	N=323	N=336		
Nausea, %	31	30	57	15	17	52		
Anemia, [†] %	29	32	55	5	10	41		
Neutropenia, [†] %	44	45	51	8	8	23		
Fatigue/asthenia, [†] %	40	38	49	19	20	32		
Arthralgia, %	33	32	34	29	28	27		
Constipation, %	26	25	30	11	10	15		
Diarrhea, %	29	30	30	21	21	22		
Thrombocytopenia, [†] %	19	20	28	3	5	17		
Hypertension, %	34	30	26	24	18	14		
Vomiting, %	16	16	26	10	11	22		
Leukopenia, [†] %	18	18	24	5	4	13		
Headache, %	21	20	22	19	16	18		
Abdominal pain, %	18	22	21	12	15	13		
Hypothyroidism, %	7	21	20	6	14	15		
Myalgia, %	20	22	18	13	12	9		

Includes AEs with onset or worsening on or after the date of first dose of durvalumab/placebo or olaparib/placebo (overall) or first dose of olaparib/placebo (maintenance phase) until initiation of the first subsequent anticancer therapy following last dose of study treatment or until the end the safety follow-up period. *AEs of any grade with overall incidence of ≥20% in any arm and associated incidence in the maintenance phase, excluding alopecia; †Grouped-term.





2023 **ASCO**

ANNUAL MEETING

Grade ≥3 AE with frequency of ≥5%*

	Maintenance phase					
Grade ≥3 AEs	Arm 1 PC + bev N=376	Arm 2 PC + bev + durva N=373	Arm 3 PC + bev + durva + ola N=378	Arm 1 PC + bev N=331	Arm 2 PC + bev + durva N=323	Arm 3 PC + bev + durva + ola N=336
Neutropenia, [†] %	26	28	31	2	2	9
Anemia,† %	8	8	24	<1	<1	21
Leukopenia, [†] %	4	5	8	1	<1	2
Hypertension, %	11	9	7	8	6	4
Thrombocytopenia, [†] %	4	4	6	0	<1	3

Includes AEs with onset or worsening on or after the date of first dose of durvalumab/placebo or olaparib/placebo (overall) or first dose of olaparib/placebo (maintenance phase) until initiation of the first subsequent anticancer therapy following last dose of study treatment or until the end the safety follow-up period. "Grade ≥3 AEs with overall incidence of ≥5% in any arm and associated incidence in the maintenance phase; †Grouped-term.



#ASCO23 PRESENTED BY: Dr Philipp Harter

2023 **ASCO**

ANNUAL MEETING

Conclusions

ASC

ANNUAL MEETING

#ASCO23

- DUO-O met its primary endpoint at the planned PFS interim analysis, demonstrating statistically significant and clinically meaningful improvement in PFS with first-line chemotherapy + bevacizumab + durvalumab followed by maintenance bevacizumab + durvalumab + olaparib compared with control in patients with non-tBRCAm advanced OC
 - Non-tBRCAm HRD-positive: HR 0.49 (0.34–0.69); P<0.0001
 - Non-tBRCAm ITT: HR 0.63 (0.52–0.76); P<0.0001
- PFS benefit was observed across subgroups, including those patients with HRD-negative disease (HR 0.68 [0.54–0.86])
- A numerical, but not statistical, improvement in PFS was shown with chemotherapy + bevacizumab + durvalumab followed by maintenance bevacizumab + durvalumab, compared with control, in the non-tBRCAm ITT population at the time of the PFS interim analysis
- Safety was generally consistent with the known profiles of each individual agent
- The trial is ongoing final PFS, OS and other key secondary results will be reported in due course



Scan for:

- Slides
- Plain-language infographic
- Patient lay summary

(https://www.cancer.net/DUO-O)

Copies of this slide deck obtained through quick response (QR) code are for personal use only and may not be reproduced without written permission from $ASCO^{\circledast}$ or the authors of these slides



Acknowledgments

Canada

Xing Zeng

Lacev Pitre

Diane Provencher

Prafull Ghatage

Marie Pierre Bernard

Gitte-Bettina Nyvang

Charlotte Haslund

Jørn Herrstedt

Christian Wulff

Sakari Hietanen

Ulla Puistola

France

Henna Kärkkäinen

Coriolan Lebreton

Nicolas Delanov

Fernando Bazan

Jean-Sébastien Frenel

Laurence Venat-Bouvet

Marie-Liesse Joulia

Olivier Tredan

Alain Lortholary

Renaud Sabatier

Frédéric Selle

Parvin Adimi

Finland

We thank all the women, their families, the investigators, the IDMC and the staff who participated in this study

Austria

Christian Marth Alexander Reinthaller **Clemens Schmitt** Edgar Petru

Belgium

Jessica Singh Els Van Nieuwenhuysen Vincent Castonguav Greet Huygh Susie Lau Caroline Lamot Isabelle Spoormans Stephanie Henry Denmark

Brazil

Roberto Hega Vitor Liutti Eduardo Costa e Silva Christina Opperman Kussler Felipe Cruz Cristiano Souza Katsuki Tiscoski Andreia de Melo

Bulgaria

Mila Petrova Vasil Popov Antoaneta Tomova Assia Konsoulova-Kirova

Germany Philipp Harter Stephanie Lheureux

Fabian Trillsch Pauline Wimberger Claus-Henning Köhne Hans-Joachim Lück Felix Hilpert Dominik Denschlag Annette Hasenburg Matthias Kögel Andreas Schnelzer **Daniel Rein Dietrich Hager** Pawel Mach Tjoung-Won Park-Simon Dirk Bauerschlag Eva Maria Grischke Zaher Alwafai Lars Hanker **Toralf Reimer** Alexander Burges Uwe Herwig Wencke Ruhwedel Jalid Sehouli Fabienne Schochter Jan Stratmann Beate Rautenberg Gabriele Feisel-Schwickardi Barbara Schmalfeldt Jens Kosse Michael Weigel Werner Bader Oliver Tomé **Bahrive Aktas** Marie-Christine Kaminsky Andreas Müller Björn Lampe Claudia Hänle

Cornelia Müller Alexander Hein Ingo Runnebaum Lucia Otten Frederik Marmé

Hungary Robert Poka Judit Oláh Istvan Sipocz

Zsuzsanna Pápai Andrea Bagaméri Károly Máhr András Bálint

Italy Nicoletta Colombo Giovanni Scambia Annamaria Ferrero Germana Tognon Antonio Ardizzoia Stefania Napolitano Giorgia Mangili Donata Sartori Pietro Del Medico Graziana Ronzino

Peru

Vanessa Bermudez Carmen Acevedo Natalia Valdiviezo Carlos Aliaga Paolo Valdez Henry Gomez Jose Revilla

Turkey Mehmet Ali Vardar

Ali Avhan Nejat Ozgul Avdin Ozsaran Serkan Keskin Haci Mehmet Turk

United States of

America Carol Aghaianian Joyce Barlin Sharad Ghamande Sudarshan Sharma Kathv Miller Michael Gold Angeles Alvarez Secord Paul Celano Gottfried Konecny Krishnansu Tewari Robert M. Wenham Edwin Alvarez **Thomas Buekers** Thomas Reid Albert Bonebrake Lainie Martin Theresa Werner Floor Backes Devansu Tewari Russell Schilder **Bethany Bustamante** Eirwen Miller

Japan Aikou Okamoto

Nozomu Yanaihara Junzo Hamanishi Masao Okadome Hidenori Kato Hideki Tokunaga Masayuki Sekine Nobuhiro Kado Shin Nishio Hirokuni Takano Mayu Yunokawa Masahiko Mori Kosuke Tsuji Takuya Aoki Hiroyuki Nomura Keiichiro Nakamura

China

Rutie Yin





Funding This study was funded by AstraZeneca

Medical writing support Provided by Abbie Newman, BSc, of Cence, funded by AstraZeneca



2023 **ASCO** #ASCO23 ANNUAL MEETING

Romania Andrei Ungureanu

María Jesús Rubio Pérez Luis Manuel Manso Sanchez Raúl Márquez Vázquez Eva María Guerra Julen Fernández Plana Isaura Fernández Pérez Antonio Casado Herraez

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.

Spain

Poland

Mariusz Bidziński

Joanna Pikiel

Piotr Potemski

South Korea

Jae-Weon Kim

Jung-Yun Lee

Yong Beom Kim

Myong Cheol Lim

Byoung-Gie Kim

Suk-Joon Chang

Renata Duchnowska

Anita Chudecka-Głaz